Article in PDF
How to Cite
Citation Manager
Readers' Comments (0)
Audio Visual Article Statistics
Link
to PUBMED
Print this Article
Send to a Friend
Advertisers
Access Statistics Resources
Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."
Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011
Dr. Shankar P.R.
"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."
Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011 Anuradha
Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.
Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020
Case report
Full Version
Hairy Cell Leukaemia with Leucocytosis: A Rare Case Report with Review of Literature
Correspondence Address :
Dr. Parul,
Senior Resident, Department of Pathology, BPS Government Medical College (W), Khanpur Kalan, Sonipat-131305, Haryana, India.
E-mail: parul.smgs@gmail.com
Hairy Cell Leukaemia (HCL) is an uncommon disease that accounts for 2% of all lymphoid leukaemias. It is characterised by the proliferation of lymphoid cells with abundant cytoplasm with circumferential fine hairy projections involving the peripheral blood, Bone Marrow (BM), and expanding splenic red pulp. A 50-year-old male presented to the medicine outpatient department with a history of weakness and breathlessness for three days hampering his daily chores. There was no history of any other chronic illness. The review of the peripheral blood smear demonstrated marked leucocytosis showing lymphocytosis. Some of these lymphocytes displayed hairy cytoplasmic projections. Red blood cells showed a dimorphic blood picture. BM aspiration was performed which was insufficient for opinion. BM cell block revealed mononuclear cells with perinuclear clearing giving a fried egg appearance. BM biopsy revealed a predominance of mononuclear cells with round nuclei suggestive of lymphoid cells. These cells showed an interstitial pattern of infiltration. Clear zones are seen around the nucleus (fried egg appearance). A diagnosis of lymphoproliferative disorder with the closest resemblance to HCL was made which was confirmed on Flow Cytometry (FCM) with these lymphoid cells showing positivity for CD45, CD20, CD25, and CD123. HCL with leukocytosis is relatively a rare presentation. Immunophenotyping plays a crucial role in making its diagnosis.
Bone marrow, Fried egg appearance, Lymphoid cell
A 50-year-old man presented to the outpatient department of medicine with a history of weakness for one month and breathlessness for three days. There was no associated history of numbness, fever, cough, nausea, vomiting, and headache. Also, there was no history of any other chronic illness. On systemic examination, hepatosplenomegaly was present. Haematological examination revealed the following findings (Table/Fig 1).
Peripheral blood smear examination revealed leukocytosis with 93% atypical lymphoid cells, 4% monocytes, and 3% polymorphs. These neoplastic cells were small to medium sized, characterised by a round to indented nucleus, homogenous ground glass chromatin, and inconspicuous nucleoli. These cells had abundant pale blue cytoplasm with circumferential hairy projections (Table/Fig 2). Additionally, the red blood cell morphology exhibited a dimorphic pattern, characterised predominantly by microcytic hypochromic anaemia and markedly reduced platelets with normal morphology. BM aspiration was markedly haemodiluted. BM biopsy revealed hypercellular marrow with a predominance of neoplastic mononuclear cells infiltrating marrow in the interstitial pattern. These atypical lymphoid cells had single oval to round nuclei, abundant clear cytoplasm, and prominent cell borders producing fried egg appearance (Table/Fig 2). There was a reduction in normal haematopoietic elements with an occasional group of erythroid cells showing micronormoblastic maturation. The myeloid series was reduced in number with occasional eosinophils along with few interspersed megakaryocytes. Based on clinical, peripheral blood and BM findings, a provisional diagnosis of HCL was given.
Further, FCM was performed with 89% of the gated events on side scatter/CD19 plots revealed CD19, CD20, CD25, CD123, and CD45 positivity (Table/Fig 2). Final diagnosis of HCL was given. The patient remained almost asymptomatic for next one year and received only supportive treatment in the form of haematinics and two blood transfusions. However, six months ago, he began experiencing weakness which was progressively increasing. He was referred to a higher center where he underwent three cycles of chemotherapy and symptomatic improvement was observed as per information received telephonically from patient.
The HCL is a mature lymphoid B cell disorder with an incidence of 2% of lymphoid leukaemias. Classical triad of HCL presents with splenomegaly, pancytopenia, and hairy cells in BM but leucocytosis may be rarely observed in only 10-20% of HCL cases. In 1923, Ewald introduced the term leukaemic reticuloendotheliosis to describe a haematologic disorder marked by splenomegaly, pancytopenia, and circulating monocytic cells. Further, this entity was recognised by Bouroncle, Wiseman, and Doan as a distinct clinicopathologic entity in 1958 and since then it has undergone enormous advances (1),(2). HCL was recognised as an entity by the World Health Organisation (WHO) since in 2008. It was included under the category of mature B cell neoplasms and the HCL variant was classified under the subcategory of splenic lymphoma/leukaemia unclassifiable (3). However, in the latest 2022 revision of the WHO classification of lymphoid neoplasms, HCL is included under the category of splenic B cell leukaemia/lymphoma along with splenic marginal zone lymphoma, splenic diffuse red pulp small B cell lymphoma and splenic B cell lymphoma/leukaemia with prominent nucleoli encompassing HCL variant (4).
It is a mature lymphoid B cell disorder that is characterised by the identification of hairy cells in peripheral blood smear and BM, a specific immunophenotype profile, a different clinical course, and the need for appropriate treatment. Late activated post germinal center memory B cells and splenic marginal zone B cells are possibly considered as the cell for its origin. Unlike most mature B cell malignancies, it usually lacks lymph node involvement but often presents with splenomegaly with involvement of red pulp, atrophy of white pulp, and pancytopenia (5). It shows a higher incidence in males with an M:F ratio- 4:1 and a median onset age of 52 years (6). Typical symptoms include fatigue, weight loss, fever, bleeding, moderate to massive splenomegaly, and hepatomegaly in approximately 50% of cases. Recurrent infections are a significant manifestation and leading cause of mortality (7).
Various differential diagnosis for HCL include reactive lymphocytosis, chronic lymphocytic leukaemia, prolymphocytic leukaemia, splenic diffuse red pulp small B cell lymphoma, splenic marginal zone lymphoma, and mantle cell lymphoma. Chronic lymphocytic leukaemia is characterised by small, mature-looking lymphocytes on peripheral film which express CD5 and lacking expression of CD103. Prolymphocytic leukaemia is defined by the presence of >55% prolymphocytes in peripheral smear which are medium to large size lymphoid cells with round to indented nuclei and prominent nucleolus. These cells express positivity for CD20, CD79a, and CD79b and lack expression of CD23 (8).
Splenic diffuse red pulp small B cell lymphoma features massive splenomegaly and atypical lymphoid cells with broad base cytoplasmic extensions in the polar distribution in circulation. These atypical lymphoid cells lack expression of CD25. Splenic marginal zone lymphoma presents with massive splenomegaly and small lymphocytes with fine villous cytoplasmic projections in circulation which are characterised by the lack of expression of CD103, CD11c and CD25. Mantle cell lymphoma may show small to medium monomorphic lymphoid cells with inconspicuous nucleoli. These cells strongly express cyclin D1 but do not express CD25 or CD103 (8).
The Complete Blood Count (CBC) and careful review of the peripheral blood smear is the first step in its identification. The neoplastic cells are typically sparse in circulation and display round to oval nuclei with indentation, abundant cytoplasm, and discernible circumferential hairy projections in both peripheral blood and BM (9). As per WHO 5th edition, 2022 (WHO-HAEM5), an immunological scoring system was proposed based on expression of CD11c, CD103, CD123, and CD25, assigning one point to each marker when expressed. A score of 3 or 4 is observed in 98% of cases of HCL whereas in HCL-like disorders the score is usually 0 or 1. These hairy cells are negative for CD5, CD23, CD10 and, CD27. Also, the neoplastic cells can infiltrate BM, thus BM study is crucial for determining the extent of BM involvement and to aid in the diagnosis of challenging cases in which immunohistochemical markers like CD 20, CD 72, and annexin A1 are used to reach the final diagnosis. Annexin A1 is considered as most specific marker since it is not expressed in any B cell lymphoma other than HCL (10),(11).
Factors such as splenomegaly exceeding 3 cm above normal, leukocytosis over 1000/μL, the presence of more than 5000/μL hairy cells in the blood, elevated beta2 microglobulin levels more than twice the normal value, increased lactic dehydrogenase, and unmutated Immunoglobulin Heavy-Chain Variable (IGVH) are indicative of a poor prognosis (12). Treatment is administered only in symptomatic cases or when haematological parameters are deteriorating. The specific haematological criteria indicating the need for treatment include any of the following: haemoglobin levels below 11 gm/dL, platelet count less than 100,000/μL, or an absolute neutrophil count below 1,000/μL. Additionally, symptomatic splenomegaly may also warrant treatment (10),(13).
In a study by Galani KS et al., conducted in Mumbai in 2012, 28 cases of HCL were included which were diagnosed over a period of nine years and only two cases (7.14%) were documented with leukocytosis. Patients’ ages ranged from 26-69 years with a median age of 47 years, with M:F-6:1. Physical examination revealed splenomegaly in 92% and hepatomegaly in 28% of patients (14). In another study by Patel K et al., from Gujarat in 2018, done over a period of four years and diagnosed 18 cases of HCL among 300 chronic lymphoproliferative disorders with only four cases (22.2%) of HCL presented with leukocytosis. Patients’ ages ranged from 35 to 69 years with male predominance (M:F-6:1) and clinical findings of splenomegaly (78%) and hepatomegaly (22%). Immunophenotype indicated CD19 gated on lymphocytes with co-expression of CD103, CD11c, and CD25 (15). They concluded that HCL can occur at a younger age, potentially due to geographical factors with unusual presentations like lymphadenopathy and leukocytosis. In another study by Chatterjee T et al., 15 cases of HCL were studied over a period of two years of which only one case (6.6%) had leukocytosis (16). (Table/Fig 3) discuss the review of literature of HCL case reported with leukocytosis (7),(8),(15),(16),(17).
In a study by Adley BP et al., it was concluded that patients with HCL usually present with pancytopenia and only rarely with leukocytosis. This rare presentation of HCL should be kept in mind in order to provide accurate diagnosis and proper treatment of this disease (9).
In a case reported by Fugere T et al., a 44-year-old male presented with dizziness and history of falling on the ground. Initial laboratory results revealed leukocytosis (25,000/mm3), anaemia (3 gm/dL), and thrombocytopenia (31000/mm3) (18). Imaging study revealed a subdural haematoma, massive splenomegaly and diffuse lymphadenopathy. FCM revealed CD45 bright neoplastic B cells with bright co-expression of CD19 and CD22, dimmer CD20, CD25, CD103, CD23, CD200, and FMC7 and were negative for CD5 and CD10. The patient was given cladribine and rituximab which was continued on weekly basis for four weeks after completion of the cladribine. After the fourth cycle of rituximab, his haemoglobin improved to >11 g/dL, platelets to >100,000/μL, and absolute neutrophil count to >1500/μL, indicating a complete response (18).
Single case reports of HCL presenting with leukocytosis were also observed by Sapre JP et al., Kataria SP et al., and Kumari L et al., (7),(17),(19). In all these cases, the detection of hairy cells in peripheral blood associated with leukocytosis clinched the diagnosis however final diagnosis was confirmed by immunophenotyping.
Our case also represents another uncommon instance of HCL, with diagnosis confirmed through morphology and immunophenotyping. Furthermore, this case along with potentially preceding cases highlights that while HCL typically presents with pancytopenia, rare occurrences may manifest with significant leukocytosis. This potentiality should be considered to ensure early diagnosis and appropriate treatment. This disease is curable and notably responsive to nucleosides (purine analogs). Delayed diagnosis due to atypical disease presentation may result in preventable mortality.
This case highlights that the possibility of HCL should be suspected in all patients presenting with atypical lymphocytosis and splenomegaly. Although immunophenotyping is essential for confirming the diagnosis, most cases are picked by insightful observation of hairy cells in peripheral smear examination by pathologists.
DOI: 10.7860/JCDR/2025/75230.20720
Date of Submission: Sep 04, 2024
Date of Peer Review: Nov 12, 2024
Date of Acceptance: Dec 14, 2024
Date of Publishing: Mar 01, 2025
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Sep 09, 2024
• Manual Googling: Dec 03, 2024
• iThenticate Software: Dec 12, 2024 (17%)
ETYMOLOGY: Author Origin
EMENDATIONS: 6
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase
- EBSCOhost
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)
- www.omnimedicalsearch.com